UNICEF recently announced it had awarded a contract with a value of up to USD 170 million that will lead to 18 million doses of Mosquirix™ RTS,S/AS01 (RTS,S) being available over the next three years, potentially saving thousands of lives every year.
GSK's Mosquirix is a recombinant malaria vaccine that is the first and only malaria vaccine shown in pivotal long-term clinical trials to reduce malaria in children significantly.
Malaria Vaccine Supply Significantly Increases
Surgical Procedure Volumes Dropped During COVID-19 Peak
During post-COVID-19-peak period, partial recovery was seen to 85.8 percent of pre-COVID-19-peak volumes, with variation across subspecialties
Pandemic Tied to Worse Pregnancy-Related Complications, Maternal Death
However, no worsening observed in preexisting racial and ethnic disparities
Pediatric Populations Less Likely to Get Long COVID
Vaccination tied to lower risk for persistent COVID-19 symptoms at more than 12 weeks since infection